Xia Yiming, Fu Shunli, Ma Qingping, Liu Yongjun, Zhang Na
Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 Wenhua Xi Road, Jinan, 250012, Shandong, People's Republic of China.
Nanomicro Lett. 2023 Jun 3;15(1):145. doi: 10.1007/s40820-023-01125-2.
Immunotherapy has become a promising research "hotspot" in cancer treatment. "Soldier" immune cells are not uniform throughout the body; they accumulate mostly in the immune organs such as the spleen and lymph nodes (LNs), etc. The unique structure of LNs provides the microenvironment suitable for the survival, activation, and proliferation of multiple types of immune cells. LNs play an important role in both the initiation of adaptive immunity and the generation of durable anti-tumor responses. Antigens taken up by antigen-presenting cells in peripheral tissues need to migrate with lymphatic fluid to LNs to activate the lymphocytes therein. Meanwhile, the accumulation and retaining of many immune functional compounds in LNs enhance their efficacy significantly. Therefore, LNs have become a key target for tumor immunotherapy. Unfortunately, the nonspecific distribution of the immune drugs in vivo greatly limits the activation and proliferation of immune cells, which leads to unsatisfactory anti-tumor effects. The efficient nano-delivery system to LNs is an effective strategy to maximize the efficacy of immune drugs. Nano-delivery systems have shown beneficial in improving biodistribution and enhancing accumulation in lymphoid tissues, exhibiting powerful and promising prospects for achieving effective delivery to LNs. Herein, the physiological structure and the delivery barriers of LNs were summarized and the factors affecting LNs accumulation were discussed thoroughly. Moreover, developments in nano-delivery systems were reviewed and the transformation prospects of LNs targeting nanocarriers were summarized and discussed.
免疫疗法已成为癌症治疗中一个很有前景的研究“热点”。“战士”免疫细胞在全身分布并不均匀;它们大多聚集在脾脏和淋巴结等免疫器官中。淋巴结的独特结构提供了适合多种免疫细胞存活、激活和增殖的微环境。淋巴结在适应性免疫的启动和持久抗肿瘤反应的产生中都起着重要作用。外周组织中的抗原呈递细胞摄取的抗原需要随淋巴液迁移至淋巴结,以激活其中的淋巴细胞。同时,许多免疫功能化合物在淋巴结中的积累和留存显著增强了它们的功效。因此,淋巴结已成为肿瘤免疫治疗的关键靶点。不幸的是,免疫药物在体内的非特异性分布极大地限制了免疫细胞的激活和增殖,导致抗肿瘤效果不尽人意。高效的淋巴结纳米递送系统是使免疫药物疗效最大化的有效策略。纳米递送系统已显示出在改善生物分布和增强在淋巴组织中的积累方面的优势,在实现有效递送至淋巴结方面展现出强大且有前景的前景。在此,总结了淋巴结的生理结构和递送屏障,并深入讨论了影响淋巴结积累的因素。此外,综述了纳米递送系统的进展,并总结和讨论了淋巴结靶向纳米载体的转化前景。